Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84444 | 0.85 | POLB (0.41) | HSD17B10L3MBTL1POLBNPSR1PKM | |
| SCHEMBL8260696 | 0.80 | EPHX2 (0.35) | HSD17B10L3MBTL1POLBNPSR1 | |
| SCHEMBL16072938 | 0.78 | GAA (0.38) | HSD17B10L3MBTL1POLBNPSR1PKM | |
| SCHEMBL12227427 | 0.78 | POLB (0.30) | L3MBTL1POLBNPSR1 | |
| SCHEMBL16235574 | 0.73 | CTSS (0.36) | HSD17B10L3MBTL1 | |
| SCHEMBL680281 | 0.73 | LMNA (0.39) | POLBNPSR1 | |
| SCHEMBL3644435 | 0.73 | CA1 (0.46) | — | |
| SCHEMBL20329944 | 0.71 | — | — | |
| SCHEMBL14263102 | 0.71 | — | — | |
| SCHEMBL12227426 | 0.71 | GRM5 (0.38) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | HSD17B10 3175/4885L3MBTL1 263/4885POLB 3045/4885 |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | HSD17B10 2592/4885L3MBTL1 511/4885POLB 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.